Ontology highlight
ABSTRACT:
SUBMITTER: Shirley M
PROVIDER: S-EPMC8783859 | biostudies-literature | 2022 Jan
REPOSITORIES: biostudies-literature
Targeted oncology 20211214 1
Starting with the first-in-class agent ibrutinib, the development of Bruton tyrosine kinase (BTK) inhibitors has led to dramatic improvements in the management of B-cell malignancies. Subsequently, more-highly selective second-generation BTK inhibitors (including acalabrutinib, zanubrutinib, tirabrutinib and orelabrutinib) have been developed, primarily with an aim to reduce off-target toxicities. More recently, third-generation agents including the non-covalent BTK inhibitors pirtobrutinib and ...[more]